Rep. Daniel S. Goldman bought Sarepta Therapeutics (SRPT)
Rep. Daniel S. Goldman (D-NY-10) · $15K–$50K · traded Mar 6, 2023
- Transaction
- Bought
- Amount
- $15K–$50K
- Owner
- Not stated
- Traded
- Mar 6, 2023
- Disclosed
- Apr 17, 2023
- Days to disclose
- 42
- Asset type
- Stock
- As filed
- Sarepta Therapeutics, Inc.
- Industry
- Biotechnology · Healthcare
Other trades in this filing
All of Goldman's trades →- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$50K–$100K
Sold VONOVIA SE ADR CMN (VONOY)
$50K–$100K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought VOLKSWAGEN AKTIENGESELLSCHAFT ADR CMN (VWAPY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Sold (partial) Vodafone Group Public Limited Company VOD
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought VAT GROUP AG ADR CMN (VACNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) UPM-KYMMENE OYJ ADR CMN (UPMMY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Swedbank AB (publ) SWDBY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Sumitomo Mitsui Financial Group SMFG
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold SOMPO JAPAN NIPPONKOA HLDGS IN ADR CMN (SMPNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) Shiseido Company, Limited SSDOY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought SALMAR ASA ADR CMN (SALRY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
Recent Congress trades in SRPT
- May 6, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Apr 14, 2025 · disclosed May 6, 2025
- Aug 21, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Sarepta Therapeutics SRPT
$1K–$15K · Traded Jul 14, 2023 · disclosed Aug 21, 2023 · Joint
- Jul 11, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Jun 13, 2023 · disclosed Jul 11, 2023 · Joint
- May 19, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Sold Sarepta Therapeutics SRPT
$15K–$50K · Traded Apr 10, 2023 · disclosed May 19, 2023
- Apr 20, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Sarepta Therapeutics SRPT
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 20, 2023 · Joint
- Feb 24, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
Company context for SRPT
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
SRPT: third_quarter 2026 lobbying report
H.R. 9260 - LHHS Appropriations Rare Pediatric Disease Priority Review Voucher (PRV) Program Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to Section 232
Public: Oct 19, 2026, 4:58 PM EDTOriginal source ↗SRPT: second_quarter 2026 lobbying report
H.R. 9260 - LHHS Appropriations H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to supply chain Issues related to Section 232
Public: Jul 20, 2026, 1:40 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.